Delivery Order SPE2DB24D2003-SPE2DB25FXKQ7
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,245.97 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 (100 tablets), a antimalarial medication used primarily for malaria prophylaxis and treatment in military personnel. The contract was awarded on August 7, 2025, with an ultimate completion date of August 8, 2025, under firm fixed price terms with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $13,673.47 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100, a pharmaceutical product typically used for malaria prevention and treatment. The contract was awarded on September 16, 2025, with a completion date of September 17, 2025, and employs firm fixed-price pricing with no set-aside designation, indicating competitive award. The work will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,947.11 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 100S, a combination antimalarial medication commonly used for malaria prophylaxis and treatment by military personnel. This firm fixed-price delivery order, issued on August 6, 2025, with an ultimate completion date of August 7, 2025, represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $1,117.35 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100 count) with an ultimate completion date of August 25, 2025. This firm fixed price, non-set-aside contract was awarded on August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The antimalarial medication will support federal medical supply requirements, likely for military personnel...
- The Defense Logistics Agency awarded a delivery order valued at $10,096.69 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 100 tablets, with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Atovaquone-Proguanil is an antimalarial medication commonly used for malaria prophylaxis and treatment in military...
- The Defense Logistics Agency awarded a delivery order valued at $22,857.87 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100mg tablets (100 count). This competitive, non-set-aside contract utilizes firm fixed pricing and carries an ultimate completion date of July 21, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. The medication is an...
- The Defense Logistics Agency awarded a $7,195.23 delivery order to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100 100 count tablets, with performance through May 14, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a direct pharmaceutical supply delivery under AmerisourceBergen's existing relationship with DLA. The place of performance is located in Conshohocken, Pennsylvania, AmerisourceBergen's corporate headquarters, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $7,913.94 for 100 units of Atovaquone-Proguanil 250-100, an antimalarial medication commonly used for malaria prophylaxis and treatment in military and veteran populations. This firm fixed-price delivery order, awarded July 10, 2025, with completion scheduled for July 11, 2025, represents a non-competitive set-aside contract and will be performed at the contractor's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $14,922.01 delivery order to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100 (100 tablets) on September 12, 2025, with a completion date of September 15, 2025. This is a firm fixed price order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $1,100.20 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Atovaquone-Proguanil 250-100 (100 tablets). This is a firm fixed-price delivery order with no set-aside designation, demonstrating that the award was competitively procured. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 30, 2025. This delivery order is issued under...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXKQ7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,273.76 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 100S, a combination antimalarial medication. The contract was competitively awarded with no set-aside designation and carries a firm fixed price structure, with an ultimate completion date of July 16, 2025. Performance will take place at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. This prime pharmaceutical supply vehicle enables the company to deliver a comprehensive range of medications, vaccines, and medical supplies to support military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement and has demonstrated consistent capability to meet DLA requirements through competitive contracting across multiple therapeutic domains and customer bases including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 7/15/25 |